**11. Conclusions**

AKI leads to increased health care costs in each country, with higher morbidity and mortality. Detection of risk factors, early diagnosis, and use of severity classification systems and biomarkers are necessary for a timely preventive and therapeutic approach.

It is important to assess trends in creatinine elevation and consider the use of KeGFR along with KDIGO, the use of biomarkers, and FST as tools that give a clear scenario of renal capacity that may not be able to support the magnitude of severity of a critically ill patient.

The controversy generated about the ideal time to initiate KRT in critically ill patients is currently supported by evidence from RCTs and meta-analyses that support waiting in the classic "late" indications, taking into account the waiting limits suggested by the AKIKI trial 2.
